Goldberg J A, Kerr D J, Watson D G, Willmott N, Bates C D, McKillop J H, McArdle C S
University Department of Surgery, Glasgow Royal Infirmary, UK.
Br J Cancer. 1990 Jun;61(6):913-5. doi: 10.1038/bjc.1990.204.
The pharmacokinetics of 5-fluorouracil (5FU) following its administration via the hepatic artery in conjunction with biodegradable albumin microspheres and angiotensin II have been studied. Peripheral venous concentrations of 5FU are lower and plasma clearance values higher following intrahepatic arterial administration compared with a similar dose administered by intravenous infusion over both 2 h and 24 h. For the 2 h drug infusions, plasma 5FU concentrations following co-treatment with angiotensin II and microspheres via the hepatic artery were intermediate between those of arterial and venous infusions of 5FU alone. There was a trend towards the peak plasma drug concentrations and the area under the plasma concentration-time curve (AUC) being significantly lower following co-treatment with angiotensin II and microspheres compared with intra-arterial and intravenous infusions of 5FU over 24 h. Co-administration of 5FU, angiotensin II and microspheres via the hepatic artery may reduce drug exposure in the systemic compartment and therefore may increase the therapeutic ratio of 5FU administration via the hepatic artery.
研究了5-氟尿嘧啶(5FU)与可生物降解白蛋白微球及血管紧张素II联合经肝动脉给药后的药代动力学。与在2小时和24小时内静脉输注相同剂量的5FU相比,肝动脉内给药后5FU的外周静脉浓度较低,血浆清除率较高。对于2小时的药物输注,经肝动脉与血管紧张素II和微球联合治疗后的血浆5FU浓度介于单独动脉输注和静脉输注5FU的浓度之间。与24小时内动脉输注和静脉输注5FU相比,经血管紧张素II和微球联合治疗后,血浆药物浓度峰值和血浆浓度-时间曲线下面积(AUC)有显著降低的趋势。经肝动脉联合给予5FU、血管紧张素II和微球可能会减少全身循环中的药物暴露,因此可能会提高经肝动脉给予5FU的治疗指数。